Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the 40th Annual J.P.

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. Eastern Time. This esteemed conference is a significant platform for healthcare companies to share insights and updates.

A webcast of the presentation will be accessible on the Investor Relations section of Vericel's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.

Argus Session date unavailable

-1.44% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was -1.44%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Vericel's presentation at the J.P. Morgan Healthcare Conference?

Vericel's presentation will take place on January 12, 2022, at 7:30 a.m. Eastern Time.

Where can I watch the Vericel presentation?

The presentation will be available as a webcast on the Investor Relations section of the Vericel Corporation website.

What are the main products offered by Vericel Corporation?

Vericel markets MACI® for knee cartilage repair and Epicel® for skin replacement in burn treatment.

What is the stock symbol for Vericel Corporation?

The stock symbol for Vericel Corporation is VCEL.

What is the focus of Vericel Corporation's business?

Vericel Corporation specializes in advanced therapies for sports medicine and severe burn care.